OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. The company has market cap of $13.61 million. The Company’s lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. It currently has negative earnings. The firm is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion.
The stock of Arlington Asset Investment Corp. (NYSE:AI) is a huge mover today! The stock increased 1.71% or $0.2 during the last trading session, reaching $11.9. About 185,512 shares traded. Arlington Asset Investment Corp. (NYSE:AI) has risen 15.91% since March 13, 2017 and is uptrending. It has underperformed by 0.79% the S&P500.The move comes after 6 months positive chart setup for the $335.58M company. It was reported on Mar, 13 by Barchart.com. We have $12.97 PT which if reached, will make NYSE:AI worth $30.20 million more.
Garrison Bradford & Associates Inc holds 0.3% of its portfolio in OHR Pharmaceutical, Inc. for 497,415 shares. Leisure Capital Management owns 64,067 shares or 0.04% of their US portfolio. Moreover, Cannell Peter B & Co Inc has 0.01% invested in the company for 292,858 shares. The Missouri-based Cutter & Co Brokerage Inc. has invested 0.01% in the stock. Sabby Management Llc, a New Jersey-based fund reported 152,127 shares.
The stock decreased 1.55% or $0.0038 during the last trading session, reaching $0.241. About 368,060 shares traded. OHR Pharmaceutical, Inc. (OHRP) has declined 77.87% since March 13, 2017 and is downtrending. It has underperformed by 94.57% the S&P500.
Analysts await Arlington Asset Investment Corp. (NYSE:AI) to report earnings on April, 24. They expect $0.36 EPS, up 63.64% or $0.14 from last year’s $0.22 per share. AI’s profit will be $10.15 million for 8.26 P/E if the $0.36 EPS becomes a reality. After $0.25 actual EPS reported by Arlington Asset Investment Corp. for the previous quarter, Wall Street now forecasts 44.00% EPS growth.
Among 9 analysts covering Arlington Asset Investment (NYSE:AI), 3 have Buy rating, 0 Sell and 6 Hold. Therefore 33% are positive. Arlington Asset Investment had 21 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of Arlington Asset Investment Corp. (NYSE:AI) has “Buy” rating given on Wednesday, January 10 by Maxim Group. The rating was maintained by MLV on Friday, July 31 with “Hold”. B. Riley & Co maintained the shares of AI in report on Friday, February 9 with “Neutral” rating. Barclays Capital maintained Arlington Asset Investment Corp. (NYSE:AI) rating on Thursday, May 12. Barclays Capital has “Equalweight” rating and $14 target. The stock of Arlington Asset Investment Corp. (NYSE:AI) earned “Buy” rating by Compass Point on Wednesday, July 29. The firm has “Buy” rating by Maxim Group given on Wednesday, October 28. The stock has “Neutral” rating by Ladenburg Thalmann on Wednesday, July 29. The company was maintained on Thursday, October 27 by Wunderlich. The stock of Arlington Asset Investment Corp. (NYSE:AI) earned “Buy” rating by Maxim Group on Wednesday, October 25. FBR Capital downgraded Arlington Asset Investment Corp. (NYSE:AI) rating on Tuesday, December 20. FBR Capital has “Mkt Perform” rating and $16 target.
Arlington Asset Investment Corp., an investment firm, acquires mortgage-related and other assets. The company has market cap of $335.58 million. The firm acquires on a leveraged basis residential mortgage-backed securities that are issued by the United States (U.S.) government agency, or guaranteed as to principal and interest by U.S. government agencies, or U.S. government-sponsored entities. It has a 18.03 P/E ratio. It also acquires MBS issued by private organizations.